Cargando…

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas

PURPOSE: Although the usefulness of O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation analysis for predicting response to chemoradiotherapy and the prognosis of patients with glioblastoma has been widely reported, there is still no consensus regarding how to define MGMT promoter m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hosoya, Tomohiro, Takahashi, Masamichi, Honda-Kitahara, Mai, Miyakita, Yasuji, Ohno, Makoto, Yanagisawa, Shunsuke, Omura, Takaki, Kawauchi, Daisuke, Tamura, Yukie, Kikuchi, Miyu, Nakano, Tomoyuki, Yoshida, Akihiko, Igaki, Hiroshi, Matsushita, Yuko, Ichimura, Koichi, Narita, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072488/ https://www.ncbi.nlm.nih.gov/pubmed/35397757 http://dx.doi.org/10.1007/s11060-022-03999-5

Ejemplares similares

Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence
por: Kawauchi, Daisuke, et al.
Publicado: (2023)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma
por: Ohno, Makoto, et al.
Publicado: (2022)

Early Diagnosis and Surgical Intervention Within 3 Weeks From Symptom Onset Are Associated With Prolonged Survival of Patients With Glioblastoma
por: Kawauchi, Daisuke, et al.
Publicado: (2022)

ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
por: Kikuchi, Miyu, et al.
Publicado: (2021)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas
por: Omura, Takaki, et al.
Publicado: (2022)

HGG-39. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RADIATION-INDUCED GLIOMA
por: Ohno, Makoto, et al.
Publicado: (2020)

STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
por: Ohno, Makoto, et al.
Publicado: (2021)

MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
por: Ohno, Makoto, et al.
Publicado: (2019)

NQPC-10 END-OF-LIFE PHASE OF GLIOBLASTOMA
por: Omura, Tomoko, et al.
Publicado: (2019)

COT-23 INITIAL EXPERIENCE OF TREATMENT FOR GLIOBLASTOMA BY NOVO-TTF
por: Omura, Takaki, et al.
Publicado: (2019)

NQPC-14 COMPARISON OF QOL SCALES IN PATIENTS WITH BRAIN TUMORS
por: Satomi, Natsuko Tsushita, et al.
Publicado: (2019)

Combination of asleep and awake craniotomy as a novel strategy for resection in patients with butterfly glioblastoma: Two case reports
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma
por: Ohno, Makoto, et al.
Publicado: (2019)

NQPC-13 THE EFFICACY OF RAVEN’S COLORED PROGRESSIVE MATRICES FOR PATIENTS WITH BRAIN TUMOR
por: Yahiro, Sachiko, et al.
Publicado: (2019)

NQPC-10 IMPACT OF HEALTH-RELATED QOL (HRQOL) IN THE FIRST SIX MONTHS AFTER SURGERY ON LONG-TERM POSTOPERATIVE GENERAL HEALTH STATUS IN GLIOMA PATIENTS
por: Kugasawa, Kazuha, et al.
Publicado: (2022)

ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022)

MET-10 A SINGLE CENTER RETROSPECTIVE ANALYSIS OF AWAKE CRANIOTOMY FOR METASTATIC BRAIN TUMOR
por: Yanagisawa, Shunsuke, et al.
Publicado: (2022)

COT-04 FAMILY SUPPORT FOR PATIENTS WITH PRIMARY MALIGNANT BRAIN TUMORS BY PATIENT SUPPORT GROUP IN NATIONAL CANCER CENTER
por: Horikawa, Mayumi, et al.
Publicado: (2019)

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients
por: Quillien, Véronique, et al.
Publicado: (2014)

RT-5 Boron Neutron Capture Therapy has extended progression-free survival about recurrent malignant peripheral nerve sheath tumor - A case report
por: Watanabe, Yuko, et al.
Publicado: (2021)

Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies
por: Ohno, Makoto, et al.
Publicado: (2022)

COT-15 LITERATURE REVIEW ON THE DECISION MAKING OF THE BRAIN TUMOR PATIENT
por: Kishi, Tatsuya, et al.
Publicado: (2019)

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
por: Natsume, Atsushi, et al.
Publicado: (2022)

Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer
por: Imaizumi, Jun, et al.
Publicado: (2023)

INTRAVASCULAR LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM PRESENTING AS MULTIPLE CEREBRAL INFARCTIONS
por: MOMOTA, HIROYUKI, et al.
Publicado: (2012)

MPC-1 DNA methylome analysis suggested the presence of “true” IDH-wildtype lower-grade gliomas
por: Satomi, Kaishi, et al.
Publicado: (2021)

A rare case of brain metastasis from poorly differentiated small bowel adenocarcinoma
por: Yamazawa, Erika, et al.
Publicado: (2019)

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
por: Håvik, Annette Bentsen, et al.
Publicado: (2012)

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma
por: Li, Mingxiao, et al.
Publicado: (2021)

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2022)

Prognostic factors of brain metastases from colorectal cancer
por: Imaizumi, Jun, et al.
Publicado: (2019)

PEDT-12 NATIONWIDE LANDSCAPE OF GENOMIC ANALYSIS OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS
por: Watanabe, Yuko, et al.
Publicado: (2022)

Clinical presentation of anaplastic large-cell lymphoma in the central nervous system
por: NOMURA, MASASHI, et al.
Publicado: (2013)

Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
por: Iliadis, Georgios, et al.
Publicado: (2012)

Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
por: Kim, Dae Cheol, et al.
Publicado: (2016)

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma
por: Villani, Veronica, et al.
Publicado: (2015)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g6jra9345e31ep870gecs19lfl